Page last updated: 2024-10-16

carnitine and Fatigue

carnitine has been researched along with Fatigue in 57 studies

Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.

Research Excerpts

ExcerptRelevanceReference
"Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue."9.34Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. ( Ando, H; Ikejima, K; Ishizuka, K; Kitagawa, R; Kokubu, S; Miyazaki, A; Nagahara, A; Okubo, H; Okubo, S; Saito, H; Shiina, S, 2020)
"To evaluate the potential role of levocarnitine supplementation for cancer-related fatigue in patients treated with sunitinib."9.30Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study. ( Kobayashi, K; Masumori, N; Shindo, T; Tanaka, T, 2019)
" This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancer patients in Japan."9.22Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). ( Ariyoshi, K; Doi, T; Inoue, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Miyara, K; Odagiri, H; Sagara, Y; Tsutsumi, C; Yamaguchi, T; Yotsumoto, D, 2016)
"Intravenous L-carnitine can ameliorate fasting-induced hunger, fatigue, cholesterol abnormalities and hepatic metabolic changes and facilitate fasting-induced weight loss in MetS patients."9.19L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. ( Cai, YJ; Huang, YJ; Ke, B; Qin, J; Qiu, CP; Shi, LY; Wu, ZB; Yang, YB; Zhang, JJ, 2014)
"L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population."9.16L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. ( Ansari, B; Cella, D; Cruciani, RA; Fisch, MJ; Manola, J; Zhang, JJ, 2012)
"This study evaluated the efficacy of L-carnitine on physical and mental fatigue and on cognitive functions of centenarians."9.12L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. ( Cammalleri, L; Colonna, V; Gargante, MP; Malaguarnera, M; Motta, M; Vacante, M, 2007)
"To evaluate the effect of L-carnitine treatment in fatigue in adult celiac patients."9.12L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. ( Bucci, C; Calvani, M; Ciacci, C; Iannoni, E; Iovino, P; Margarucci, S; Peluso, G; Rispo, A; Siniscalchi, M; Tortora, R; Zingone, F, 2007)
"Carnitine deficiency is among the many metabolic disturbances that may contribute to fatigue in patients with cancer."9.12Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. ( Cruciani, RA; Culliney, B; Dvorkin, E; Esteban-Cruciani, N; Homel, P; Lapin, J; Malamud, S; Portenoy, RK, 2006)
"Testosterone and carnitines significantly improved the peak systolic velocity, end-diastolic velocity, resistive index, nocturnal penile tumescence, International Index of Erectile Function score, Depression Melancholia Scale score, and fatigue scale score."9.11Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. ( Biagiotti, G; Caracciolo, S; Cavallini, G; Modenini, F; Vitali, G, 2004)
" In studies with positive quality ratings, a meta-analysis was performed using the random-effects model on Carnitine and cancer-related fatigue."8.95Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. ( Isenring, E; Itsiopoulos, C; Kelly, J; Marshall, S; Marx, W; Opie, RS; Teleni, L, 2017)
"Objective In the present study, we prospectively examined the efficacy of levocarnitine in relieving symptoms of fatigue in patients with cirrhosis but without overt hepatic encephalopathy."8.02The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2021)
"Low serum carnitine levels have been reported in patients with cancer receiving chemotherapy and are considered one of the factors causing fatigue associated with chemotherapy."7.96[Effectiveness of L-Carnitine in the Treatment of Fatigue Associated with Chemotherapy in Patients with Gastric Cancer]. ( Akiyama, H; Endo, I; Kosaka, R; Kunisaki, C; Masuda, M; Miyamoto, H; Sato, K; Sato, S; Tanaka, Y; Watanabe, H; Yukawa, N, 2020)
"This study suggests that there is an association between urinary carnitine levels and self-reported fatigue."7.85Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy. ( Ikezaki, T; Inomata, M; Kajiura, S; Kambara, K; Kashii, T; Miwa, T; Okazawa, S; Suzuki, K; Tanabe, K, 2017)
" Patients completed the Pediatric Functional Assessment of Chronic Illness-Fatigue, the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale, a numeric fatigue rating, and had carnitine levels obtained."7.83A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. ( Goldman, S; Haertling, T; Lai, JS; Rademaker, AW; Weinstein, J, 2016)
" Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8."7.81Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015)
"Ten patients with advanced and recurrent cancer experiencing fatigue during chemotherapy were administered levocarnitine chloride."7.80[Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy]. ( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2014)
"To investigate the effect of fatigue and restraint stress on the expressions of CPT (carnitine palmitoyltransferase)-I, PPAR (peroxisome proliferator-activated receptor) δ, 5-HT (hydroxytryptamine) 1D and 5-HT2A receptors in aorta of rats."7.77[Effects of fatigue and restraint stress on the expression of carnitine palmitoyltransferase-I and 5-hydroxytryptamine receptors in aorta of rats]. ( Chang, LP; Han, JK; Jia, ZH; Wang, HT; Wei, C; Wu, YL, 2011)
"In this study, we aimed at determining the contributory role of plasma levels of leptin and carnitine on fatigue in chronic hepatitis C and IBS."7.77Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome. ( Anty, R; Bekri, S; Cherikh, F; Dainese, R; DeGalleani, L; Gelsi, E; Marjoux, S; Piche, T; Tran, A, 2011)
"The serum concentrations of total, free and acylcarnitine were compared in 25 patients with multiple sclerosis (MS) and among age- and sex-matched normal controls by the new enzymatic cycling method in order to clarify whether the fatigue in MS might be due to possible carnitine-related fatty acid metabolic abnormalities in the mitochondria of skeletal muscles."7.69Serum carnitine and disabling fatigue in multiple sclerosis. ( Fukazawa, T; Hamada, T; Kikuchi, S; Sasaki, H; Tashiro, K, 1996)
"Carnitine is an essential micronutrient that transfer long-chain fatty acids from the cytoplasm into the mitochondrial matrix for the β-oxidation."7.01Carnitine derivatives beyond fatigue: an update. ( Catania, VE; Malaguarnera, M, 2023)
"Carnitine is an essential protein for transportation of long-chain fatty acids to the matrix for beta-oxidation."6.78Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects. ( Azimi, A; Hadaegh, A; Karimi, M; Mazloom, M; Shahriari, M; Tabei, SM; Zareifar, S, 2013)
"Fatigue is a common complaint in patients with liver disease."6.71L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003)
"Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells."6.70Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002)
"Carnitine was well tolerated, and no drug-related adverse effects were identified."6.70Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. ( Adler, S; Amato, A; Brass, EP; Hiatt, WR; Orlando, AM; Sietsema, KE, 2001)
"These findings agree with previous observations among healthy adult subjects and demonstrate that L-carnitine tartrate supplementation beyond 35 days is beneficial for improving recovery and reducing fatigue following exercise across gender and age."5.41L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Bellamine, A; Durkee, S; Gheith, R; Lowery, R; Ottinger, C; Sharp, M; Stefan, M; Wilson, J, 2021)
"Fatigue is the most frequent symptom experienced by children/adolescents with cancer."5.35Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009)
"Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue."5.34Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. ( Ando, H; Ikejima, K; Ishizuka, K; Kitagawa, R; Kokubu, S; Miyazaki, A; Nagahara, A; Okubo, H; Okubo, S; Saito, H; Shiina, S, 2020)
"Fatigue is a multidimensional symptom that is described in terms of perceived energy, mental capacity, and psychological status: it can impair daily functioning and lead to negative effects on quality of life."5.33Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. ( Astara, G; Deiana, L; Dessì, M; Gramignano, G; Lamonica, G; Lusso, MR; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Serpe, R; Spiga, C, 2006)
"Patients with chronic fatigue syndrome (CFS) complain of muscle pain and impaired exercise tolerance."5.31Normal carnitine levels in patients with chronic fatigue syndrome. ( Bleijenberg, G; Elving, LD; Janssen, AJ; Soetekouw, PM; van der Meer, JW; van der Veen, Y; Vreken, P; Wevers, RA, 2000)
"To evaluate the potential role of levocarnitine supplementation for cancer-related fatigue in patients treated with sunitinib."5.30Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study. ( Kobayashi, K; Masumori, N; Shindo, T; Tanaka, T, 2019)
" This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancer patients in Japan."5.22Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). ( Ariyoshi, K; Doi, T; Inoue, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Miyara, K; Odagiri, H; Sagara, Y; Tsutsumi, C; Yamaguchi, T; Yotsumoto, D, 2016)
"Intravenous L-carnitine can ameliorate fasting-induced hunger, fatigue, cholesterol abnormalities and hepatic metabolic changes and facilitate fasting-induced weight loss in MetS patients."5.19L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study. ( Cai, YJ; Huang, YJ; Ke, B; Qin, J; Qiu, CP; Shi, LY; Wu, ZB; Yang, YB; Zhang, JJ, 2014)
"L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population."5.16L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. ( Ansari, B; Cella, D; Cruciani, RA; Fisch, MJ; Manola, J; Zhang, JJ, 2012)
"Carnitine deficiency is among the many metabolic disturbances that may contribute to fatigue in patients with cancer."5.12Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. ( Cruciani, RA; Culliney, B; Dvorkin, E; Esteban-Cruciani, N; Homel, P; Lapin, J; Malamud, S; Portenoy, RK, 2006)
"This study evaluated the efficacy of L-carnitine on physical and mental fatigue and on cognitive functions of centenarians."5.12L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. ( Cammalleri, L; Colonna, V; Gargante, MP; Malaguarnera, M; Motta, M; Vacante, M, 2007)
"To evaluate the effect of L-carnitine treatment in fatigue in adult celiac patients."5.12L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study. ( Bucci, C; Calvani, M; Ciacci, C; Iannoni, E; Iovino, P; Margarucci, S; Peluso, G; Rispo, A; Siniscalchi, M; Tortora, R; Zingone, F, 2007)
"Testosterone and carnitines significantly improved the peak systolic velocity, end-diastolic velocity, resistive index, nocturnal penile tumescence, International Index of Erectile Function score, Depression Melancholia Scale score, and fatigue scale score."5.11Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. ( Biagiotti, G; Caracciolo, S; Cavallini, G; Modenini, F; Vitali, G, 2004)
" In studies with positive quality ratings, a meta-analysis was performed using the random-effects model on Carnitine and cancer-related fatigue."4.95Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. ( Isenring, E; Itsiopoulos, C; Kelly, J; Marshall, S; Marx, W; Opie, RS; Teleni, L, 2017)
" We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis."4.91Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015)
"CAM interventions tested for cancer-related fatigue include acupuncture, aromatherapy, adenosine triphosphate infusions, energy conservation and activity management, healing touch, hypnosis, lectin-standardized mistletoe extract, levocarnitine, massage, mindfulness-based stress reduction, polarity therapy, relaxation, sleep promotion, support group, and Tibetan yoga."4.84A critical review of complementary therapies for cancer-related fatigue. ( Barton, DL; Bauer, BA; Loprinzi, CL; Sood, A, 2007)
"Some chemotherapeutic agents cause carnitine deficiency, which causes general fatigue."4.12Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia. ( Hamada, T; Hatta, Y; Iizuka, K; Iriyama, N; Koike, T; Kurihara, K; Miura, K; Nakagawa, M; Nakamura, H; Nakayama, T; Takahashi, H; Takei, M; Uchino, Y, 2022)
"Objective In the present study, we prospectively examined the efficacy of levocarnitine in relieving symptoms of fatigue in patients with cirrhosis but without overt hepatic encephalopathy."4.02The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy. ( Abe, K; Fujita, M; Hayashi, M; Ohira, H; Takahashi, A, 2021)
"Low serum carnitine levels have been reported in patients with cancer receiving chemotherapy and are considered one of the factors causing fatigue associated with chemotherapy."3.96[Effectiveness of L-Carnitine in the Treatment of Fatigue Associated with Chemotherapy in Patients with Gastric Cancer]. ( Akiyama, H; Endo, I; Kosaka, R; Kunisaki, C; Masuda, M; Miyamoto, H; Sato, K; Sato, S; Tanaka, Y; Watanabe, H; Yukawa, N, 2020)
"This study suggests that there is an association between urinary carnitine levels and self-reported fatigue."3.85Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy. ( Ikezaki, T; Inomata, M; Kajiura, S; Kambara, K; Kashii, T; Miwa, T; Okazawa, S; Suzuki, K; Tanabe, K, 2017)
" Patients completed the Pediatric Functional Assessment of Chronic Illness-Fatigue, the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale, a numeric fatigue rating, and had carnitine levels obtained."3.83A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. ( Goldman, S; Haertling, T; Lai, JS; Rademaker, AW; Weinstein, J, 2016)
" Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8."3.81Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015)
"Ten patients with advanced and recurrent cancer experiencing fatigue during chemotherapy were administered levocarnitine chloride."3.80[Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy]. ( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2014)
"In this study, we aimed at determining the contributory role of plasma levels of leptin and carnitine on fatigue in chronic hepatitis C and IBS."3.77Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome. ( Anty, R; Bekri, S; Cherikh, F; Dainese, R; DeGalleani, L; Gelsi, E; Marjoux, S; Piche, T; Tran, A, 2011)
"To investigate the effect of fatigue and restraint stress on the expressions of CPT (carnitine palmitoyltransferase)-I, PPAR (peroxisome proliferator-activated receptor) δ, 5-HT (hydroxytryptamine) 1D and 5-HT2A receptors in aorta of rats."3.77[Effects of fatigue and restraint stress on the expression of carnitine palmitoyltransferase-I and 5-hydroxytryptamine receptors in aorta of rats]. ( Chang, LP; Han, JK; Jia, ZH; Wang, HT; Wei, C; Wu, YL, 2011)
"The serum concentrations of total, free and acylcarnitine were compared in 25 patients with multiple sclerosis (MS) and among age- and sex-matched normal controls by the new enzymatic cycling method in order to clarify whether the fatigue in MS might be due to possible carnitine-related fatty acid metabolic abnormalities in the mitochondria of skeletal muscles."3.69Serum carnitine and disabling fatigue in multiple sclerosis. ( Fukazawa, T; Hamada, T; Kikuchi, S; Sasaki, H; Tashiro, K, 1996)
"Carnitine is an essential micronutrient that transfer long-chain fatty acids from the cytoplasm into the mitochondrial matrix for the β-oxidation."3.01Carnitine derivatives beyond fatigue: an update. ( Catania, VE; Malaguarnera, M, 2023)
"Carnitine is an essential protein for transportation of long-chain fatty acids to the matrix for beta-oxidation."2.78Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects. ( Azimi, A; Hadaegh, A; Karimi, M; Mazloom, M; Shahriari, M; Tabei, SM; Zareifar, S, 2013)
"Fatigue is a common complaint in patients with liver disease."2.71L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003)
"Carnitine was well tolerated, and no drug-related adverse effects were identified."2.70Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients. ( Adler, S; Amato, A; Brass, EP; Hiatt, WR; Orlando, AM; Sietsema, KE, 2001)
"Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells."2.70Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002)
"Cancer cachexia is a severe inflammatory metabolic syndrome accounting for fatigue, an impairment of normal activities and, eventually, death."2.52Advances in pharmacologic strategies for cancer cachexia. ( Gramignano, G; Macciò, A; Madeddu, C; Mantovani, G, 2015)
"Carnitine has been reported to decrease fatigue and increase endurance in older persons."2.48Ergogenic dietary aids for the elderly. ( Cherniack, EP, 2012)
"Many patients with chronic fatigue syndrome(CFS) fulfill the criteria of FMS and represent one end of a spectrum of presentation."2.40[Fibromyalgia syndrome]. ( Matsumoto, Y, 1999)
"Fatigue is the most frequent symptom experienced by children/adolescents with cancer."1.35Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009)
"Fatigue is a multidimensional symptom that is described in terms of perceived energy, mental capacity, and psychological status: it can impair daily functioning and lead to negative effects on quality of life."1.33Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. ( Astara, G; Deiana, L; Dessì, M; Gramignano, G; Lamonica, G; Lusso, MR; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Serpe, R; Spiga, C, 2006)
"Patients with chronic fatigue syndrome (CFS) complain of muscle pain and impaired exercise tolerance."1.31Normal carnitine levels in patients with chronic fatigue syndrome. ( Bleijenberg, G; Elving, LD; Janssen, AJ; Soetekouw, PM; van der Meer, JW; van der Veen, Y; Vreken, P; Wevers, RA, 2000)
"Three patients from a large consanguineous family, and one unrelated patient had exercise intolerance since early childhood and improved by supplementation with a high dosage of riboflavin."1.29Riboflavin-responsive complex I deficiency. ( Bakker, HD; Bogaard, JM; Busch, HF; Kuyt, LP; Luyt-Houwen, IE; Scholte, HR, 1995)
" We concluded that weekly short-term stimulation does not lead to a change in fiber type; however, carnitine combined with minimal stimulation of the muscle leads to a significant shift in muscle fiber type composition toward a muscle with an increased content of type I fibers."1.29L-carnitine combined with minimal electrical stimulation promotes type transformation of canine latissimus dorsi. ( De Jong, YF; Dubelaar, ML; Glatz, JF; Hülsmann, WC; Van der Veen, FH, 1994)

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (10.53)18.2507
2000's19 (33.33)29.6817
2010's22 (38.60)24.3611
2020's10 (17.54)2.80

Authors

AuthorsStudies
Stefan, M1
Sharp, M1
Gheith, R1
Lowery, R1
Ottinger, C1
Wilson, J1
Durkee, S1
Bellamine, A1
Abe, K1
Fujita, M1
Hayashi, M1
Takahashi, A1
Ohira, H1
Iriyama, N1
Miura, K1
Uchino, Y1
Takahashi, H1
Nakagawa, M1
Iizuka, K1
Hamada, T2
Koike, T1
Kurihara, K1
Nakayama, T1
Takei, M1
Hatta, Y1
Nakamura, H1
Qutob, HMH1
Saad, RA1
Bali, H1
Osailan, A1
Jaber, J1
Alzahrani, E1
Alyami, J1
Elsayed, H1
Alserihi, R1
Shaikhomar, OA1
Divya, KM1
Savitha, DP1
Krishna, GA1
Dhanya, TM1
Mohanan, PV1
Shah, SF1
Jafry, AT1
Hussain, G1
Kazim, AH1
Ali, M1
Rivani, E1
Endraswari, PD1
Widodo, ADW1
Khalil, MR1
Guldberg, R1
Nørgård, BM1
Uldbjerg, N1
Wehberg, S1
Fowobaje, KR1
Mashood, LO1
Ekholuenetale, M1
Ibidoja, OJ1
Romagnoli, A1
D'Agostino, M1
Pavoni, E1
Ardiccioni, C1
Motta, S1
Crippa, P1
Biagetti, G1
Notarstefano, V1
Rexha, J1
Perta, N1
Barocci, S1
Costabile, BK1
Colasurdo, G1
Caucci, S1
Mencarelli, D1
Turchetti, C1
Farina, M1
Pierantoni, L1
La Teana, A1
Al Hadi, R1
Cicconardi, F1
Chinappi, M1
Trucchi, E1
Mancia, F1
Menzo, S1
Morozzo Della Rocca, B1
D'Annessa, I1
Di Marino, D1
Choya, A1
de Rivas, B1
Gutiérrez-Ortiz, JI1
López-Fonseca, R1
Xu, S1
Cheng, B1
Huang, Z1
Liu, T1
Li, Y1
Jiang, L1
Guo, W1
Xiong, J1
Amirazodi, M1
Daryanoosh, F1
Mehrabi, A1
Gaeini, A1
Koushkie Jahromi, M1
Salesi, M1
Zarifkar, AH1
Studeny, P1
Netukova, M1
Nemcokova, M1
Klimesova, YM1
Krizova, D1
Kang, H1
Tao, Y1
Zhang, Q1
Sha, D1
Chen, Y1
Yao, J1
Gao, Y1
Liu, J1
Ji, L1
Shi, P1
Shi, C1
Wu, YL2
Wright, AI1
M El-Metwaly, N1
A Katouah, H1
El-Desouky, MG1
El-Bindary, AA1
El-Bindary, MA1
Kostakis, ID1
Raptis, DA1
Davidson, BR1
Iype, S1
Nasralla, D1
Imber, C1
Sharma, D1
Pissanou, T1
Pollok, JM1
Hughes, AM1
Sanderson, E1
Morris, T1
Ayorech, Z1
Tesli, M1
Ask, H1
Reichborn-Kjennerud, T1
Andreassen, OA1
Magnus, P1
Helgeland, Ø1
Johansson, S1
Njølstad, P1
Davey Smith, G1
Havdahl, A1
Howe, LD1
Davies, NM1
Amrillah, T1
Prasetio, A1
Supandi, AR1
Sidiq, DH1
Putra, FS1
Nugroho, MA1
Salsabilla, Z1
Azmi, R1
Grammatikopoulos, P1
Bouloumis, T1
Steinhauer, S1
Mironov, VS2
Bazhenova, TA2
Manakin, YV2
Yagubskii, EB2
Yakushev, IA1
Gilmutdinov, IF1
Simonov, SV1
Lan, K1
Yang, H1
Zheng, J1
Hu, H1
Zhu, T1
Zou, X1
Hu, B1
Liu, H1
Olokede, O1
Wu, H1
Holtzapple, M1
Gungor, O1
Kose, M1
Ghaemi, R1
Acker, M1
Stosic, A1
Jacobs, R1
Selvaganapathy, PR1
Ludwig, N1
Yerneni, SS1
Azambuja, JH1
Pietrowska, M1
Widłak, P1
Hinck, CS1
Głuszko, A1
Szczepański, MJ1
Kärmer, T1
Kallinger, I1
Schulz, D1
Bauer, RJ1
Spanier, G1
Spoerl, S1
Meier, JK1
Ettl, T1
Razzo, BM1
Reichert, TE1
Hinck, AP1
Whiteside, TL1
Wei, ZL1
Juan, W1
Tong, D1
Juan, LX1
Sa, LY1
Jie, HFM1
Xiao, G1
Xiang, LG1
Jie, HM1
Xu, C1
Yu, DN1
Yao, ZX1
Bigdeli, F1
Gao, XM1
Cheng, X1
Li, JZ1
Zhang, JW1
Wang, W2
Guan, ZJ1
Bu, Y1
Liu, KG1
Morsali, A1
Das, R1
Paul, R1
Parui, A1
Shrotri, A1
Atzori, C1
Lomachenko, KA1
Singh, AK1
Mondal, J1
Peter, SC1
Florimbio, AR1
Coughlin, LN1
Bauermeister, JA1
Young, SD1
Zimmerman, MA1
Walton, MA1
Bonar, EE1
Demir, D1
Balci, AB1
Kahraman, N1
Sunbul, SA1
Gucu, A1
Seker, IB1
Badem, S1
Yuksel, A1
Ozyazicioglu, AF1
Goncu, MT1
Zhang, H1
Zhou, H1
Deng, Z1
Luo, L1
Ong, SP1
Wang, C1
Xin, H1
Whittingham, MS1
Zhou, G1
Maemura, R1
Wakamatsu, M1
Matsumoto, K1
Sakaguchi, H1
Yoshida, N1
Hama, A1
Yoshida, T1
Miwata, S1
Kitazawa, H1
Narita, K1
Kataoka, S1
Ichikawa, D1
Hamada, M1
Taniguchi, R1
Suzuki, K2
Kawashima, N1
Nishikawa, E1
Narita, A1
Okuno, Y1
Nishio, N1
Kato, K1
Kojima, S1
Morita, K1
Muramatsu, H1
Takahashi, Y1
Yirgu, A1
Mekonnen, Y1
Eyado, A1
Staropoli, A1
Vinale, F1
Zac, J1
Zac, S1
Pérez-Padilla, R1
Remigio-Luna, A1
Guzmán-Boulloud, N1
Gochicoa-Rangel, L1
Guzmán-Valderrábano, C1
Thirión-Romero, I1
Statsenko, ME1
Turkina, SV1
Barantsevich, ER1
Karakulova, YV1
Baranova, NS1
Morzhukhina, MV1
Wang, Q1
Gu, Y1
Chen, C1
Qiao, L1
Pan, F1
Song, C1
Canetto, SS1
Entilli, L1
Cerbo, I1
Cipolletta, S1
Wu, Y2
Zhu, P1
Jiang, Y1
Zhang, X1
Wang, Z1
Xie, B1
Song, T1
Zhang, F1
Luo, A1
Li, S1
Xiong, X1
Han, J1
Peng, X1
Li, M1
Huang, L1
Chen, Q1
Fang, W1
Hou, Y1
Zhu, Y1
Ye, J1
Liu, L1
Islam, MR1
Sanderson, P1
Johansen, MP1
Payne, TE1
Naidu, R1
Cao, J1
Yang, J1
Niu, X1
Liu, X1
Zhai, Y1
Qiang, C1
Niu, Y1
Li, Z1
Dong, N1
Wen, B1
Ouyang, Z1
Zhang, Y1
Li, J2
Zhao, M1
Zhao, J1
Morici, P1
Rizzato, C1
Ghelardi, E1
Rossolini, GM1
Lupetti, A1
Gözüküçük, R1
Cakiroglu, B1
He, X1
Li, R1
Zhao, D1
Zhang, L1
Ji, X1
Fan, X1
Chen, J1
Wang, Y1
Luo, Y1
Zheng, D1
Xie, L1
Sun, S1
Cai, Z1
Liu, Q1
Ma, K1
Sun, X1
Drinkwater, JJ1
Davis, TME1
Turner, AW1
Davis, WA1
Suzuki, Y1
Mizuta, Y1
Mikagi, A1
Misawa-Suzuki, T1
Tsuchido, Y1
Sugaya, T1
Hashimoto, T1
Ema, K1
Hayashita, T1
Malaguarnera, M4
Catania, VE1
Okubo, H1
Ando, H1
Ishizuka, K1
Kitagawa, R1
Okubo, S1
Saito, H1
Kokubu, S1
Miyazaki, A1
Ikejima, K1
Shiina, S1
Nagahara, A1
Watanabe, H1
Kunisaki, C1
Tanaka, Y1
Sato, S1
Sato, K1
Miyamoto, H1
Yukawa, N1
Kosaka, R1
Akiyama, H1
Masuda, M1
Endo, I1
Pla, R1
Pujos-Guillot, E1
Durand, S1
Brandolini-Bunlon, M1
Centeno, D1
Pyne, DB1
Toussaint, JF1
Hellard, P1
Vasiljevski, ER1
Burns, J1
Bray, P1
Donlevy, G1
Mudge, AJ1
Jones, KJ1
Summers, MA1
Biggin, A1
Munns, CF1
McKay, MJ1
Baldwin, JN1
Little, DG1
Schindeler, A1
Ito, T1
Tsukahara, K1
Sato, H1
Shimizu, A1
Okamoto, I1
Marx, W1
Teleni, L1
Opie, RS1
Kelly, J1
Marshall, S1
Itsiopoulos, C1
Isenring, E1
Shindo, T1
Kobayashi, K1
Tanaka, T1
Masumori, N1
Endo, K1
Ueno, T1
Ishikawa, K1
Nakanishi, Y1
Kondo, S1
Wakisaka, N1
Yoshizaki, T1
Tabei, SM1
Mazloom, M1
Shahriari, M1
Zareifar, S1
Azimi, A1
Hadaegh, A1
Karimi, M1
Hooke, MC2
McCarthy, K2
Taylor, O1
Hockenberry, MJ2
Yanagawa, K1
Matsunaga, N1
Nakagawa, Y1
Zhang, JJ2
Wu, ZB1
Cai, YJ1
Ke, B1
Huang, YJ1
Qiu, CP1
Yang, YB1
Shi, LY1
Qin, J1
Macciò, A4
Gramignano, G4
Madeddu, C4
Akaishi, T1
Nakashima, I1
Misu, T1
Fujihara, K1
Aoki, M1
Mücke, M1
Cuhls, H1
Peuckmann-Post, V1
Minton, O1
Stone, P1
Radbruch, L1
Iwase, S1
Kawaguchi, T1
Yotsumoto, D1
Doi, T1
Miyara, K1
Odagiri, H1
Kitamura, K1
Ariyoshi, K1
Miyaji, T1
Ishiki, H1
Inoue, K1
Tsutsumi, C1
Sagara, Y1
Yamaguchi, T1
Mantovani, G3
Lai, JS1
Haertling, T1
Weinstein, J1
Rademaker, AW1
Goldman, S1
An, JH1
Kim, YJ1
Kim, KJ1
Kim, SH1
Kim, NH2
Kim, HY1
Choi, KM1
Baik, SH1
Choi, DS1
Kim, SG1
Benvenga, S1
Sindoni, A1
Ikezaki, T1
Kambara, K1
Inomata, M1
Okazawa, S1
Kajiura, S1
Miwa, T1
Tanabe, K1
Kashii, T1
Gregurich, M1
Fatouros, IG1
Douroudos, I1
Panagoutsos, S1
Pasadakis, P1
Nikolaidis, MG1
Chatzinikolaou, A1
Sovatzidis, A1
Michailidis, Y1
Jamurtas, AZ1
Mandalidis, D1
Taxildaris, K1
Vargemezis, V1
Anty, R1
Marjoux, S1
Bekri, S1
DeGalleani, L1
Dainese, R1
Gelsi, E1
Cherikh, F1
Tran, A1
Piche, T1
Hoofnagle, JH1
Sarkar, S1
Wei, C1
Han, JK1
Wang, HT1
Jia, ZH1
Chang, LP1
Cherniack, EP1
Cruciani, RA3
Manola, J1
Cella, D1
Ansari, B1
Fisch, MJ1
Eknoyan, G1
Latos, DL1
Lindberg, J1
Neri, S1
Pistone, G1
Saraceno, B1
Pennisi, G1
Luca, S1
Cavallini, G1
Caracciolo, S1
Vitali, G1
Modenini, F1
Biagiotti, G1
Dvorkin, E2
Homel, P2
Culliney, B2
Malamud, S2
Shaiova, L1
Fleishman, S1
Lapin, J2
Klein, E1
Lesage, P1
Portenoy, R1
Esteban-Cruciani, N2
Handelman, GJ1
Lusso, MR1
Massa, E2
Serpe, R2
Deiana, L2
Lamonica, G1
Dessì, M2
Spiga, C1
Astara, G1
Portenoy, RK1
Sood, A1
Barton, DL1
Bauer, BA1
Loprinzi, CL1
Ciacci, C1
Peluso, G1
Iannoni, E1
Siniscalchi, M1
Iovino, P1
Rispo, A1
Tortora, R1
Bucci, C1
Zingone, F1
Margarucci, S1
Calvani, M1
Mock, V1
Atkinson, A1
Barsevick, AM1
Berger, AM1
Cimprich, B1
Eisenberger, MA1
Hinds, P1
Kaldor, P1
Otis-Green, SA1
Piper, BF1
Cammalleri, L1
Gargante, MP1
Vacante, M1
Colonna, V1
Motta, M1
Tanca, FM1
Sanna, E1
Panzone, F1
Contu, P1
Floris, C1
Scholte, HR1
Busch, HF1
Bakker, HD1
Bogaard, JM1
Luyt-Houwen, IE1
Kuyt, LP1
Dubelaar, ML1
Glatz, JF1
De Jong, YF1
Van der Veen, FH1
Hülsmann, WC1
Van Wouwe, JP1
Fukazawa, T1
Sasaki, H1
Kikuchi, S1
Tashiro, K1
Matsumoto, Y1
Videen, JS1
Haseler, LJ1
Karpinski, NC1
Terkeltaub, RA1
Soetekouw, PM1
Wevers, RA1
Vreken, P1
Elving, LD1
Janssen, AJ1
van der Veen, Y1
Bleijenberg, G1
van der Meer, JW1
Brass, EP1
Adler, S1
Sietsema, KE1
Hiatt, WR1
Orlando, AM1
Amato, A1
Gomes, MR1
Tirapegui, J1
Graziano, F1
Bisonni, R1
Catalano, V1
Silva, R1
Rovidati, S1
Mencarini, E1
Ferraro, B1
Canestrari, F1
Baldelli, AM1
De Gaetano, A1
Giordani, P1
Testa, E1
Lai, V1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]42 participants (Anticipated)Interventional2020-08-01Recruiting
Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine[NCT01769157]Phase 460 participants (Actual)Interventional2012-08-31Completed
Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer[NCT00091169]Phase 3376 participants (Actual)Interventional2005-12-16Completed
Carnitine Deficiency and Benefits of Its Supplementation in Pediatric Hemodialysis Patients[NCT05948124]Early Phase 140 participants (Anticipated)Interventional2023-08-01Recruiting
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525]Phase 359 participants (Actual)Interventional2010-06-30Completed
Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306]60 participants (Anticipated)Interventional2023-05-17Recruiting
In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075]Phase 142 participants Interventional2003-09-30Completed
Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453]Phase 1/Phase 240 participants (Actual)Interventional2008-04-30Completed
Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266]Phase 294 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Score Change in Depression Measured With CES-D Between 4 Weeks and Baseline

Depression was measured using Center for Epidemiologic Studies Depression Scale (CES-D). The sum of the scores for all 20 items (range: 0-60) was used to assess depression level, and higher scores indicated a higher level of depression. Score change= CES-D score at 4 weeks - CES-D score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization

Interventionunits on a scale (Mean)
Levocarnitine-3.05
Placebo-2.91

Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks

Fatigue was measured using Brief Fatigue Inventory (BFI). The average of all 9 items included in the scale (range: 0-10) was used to measure fatigue level, and a higher average represented worse fatigue. Score change= BFI score at 4 weeks - BFI score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization

Interventionunits on a scale (Mean)
Levocarnitine-0.96
Placebo-1.11

Mean Score Change in Fatigue Measured With FACIT-F From Baseline to 4 Weeks

Fatigue was measured using Functional Assessment of Cancer Therapy- Fatigue subscale (FACIT-F). The sum of the scores for all 13 items (range: 0-52) included in the scale was used to measure fatigue level, and lower score represented worse fatigue. Score change= FACIT-F score at 4 weeks - FACIT-F score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization

Interventionunits on a scale (Mean)
Levocarnitine5.36
Placebo4.04

Mean Score Change in Pain Measured With Brief Pain Inventory From Baseline to 4 Weeks

Pain was measured using Brief Pain Inventory (BPI). The mean of the 4 severity items (range: 0-10 with 0 representing no pain and 10 representing pain as bad as you can imagine) was used to measure pain severity. Score change= BPI score at 4 weeks - BPI score at baseline. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization

Interventionunits on a scale (Mean)
Levocarnitine-0.19
Placebo-0.08

Prevalence of Carnitine Deficiency at 4 Weeks

Carnitine deficiency is defined as a ratio of acylcarnitine (total-free) to free carnitine > 0.4 μmol/L or free carnitine < 35 μmol/L for males and < 25 μmol/L for females. (NCT00091169)
Timeframe: assessed at 4 weeks after randomization

Interventionproportion of participants (Number)
Arm I0.113
Arm II0.333

Proportion of Patients With Stable or Improving Performance Status at 4 Weeks

Performance status (PS) was measured using Eastern Cooperative Oncology Group performance status scale. Lower score represents better PS. Change in PS was calculated by PS at week 4- PS at baseline. Patients with negative value for change in PS were considered to have stable or improving PS. (NCT00091169)
Timeframe: assessed at baseline and 4 weeks after randomization

Interventionproportion of participants (Number)
Arm I0.806
Arm II0.875

Anthropometric Measures of Nutritional Status (Body Mass Index [BMI] Z-scores, Weight for Length Ratios, Lean/Fat Mass Via DEXA, Growth Parameters, and Triceps Skinfold Measures)

(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months

Interventiong (Mean)
Lean Mass BaselineLean Mass 3 monthsLean Mass 6 monthsFat Mass BaselineFat Mass 3 monthsFat Mass 6 months
SMA Type 14317.154993.925133.833011.373618.254316.08

Max CMAP Amplitude (Mean)

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment2.282.32
Cohort 1b Sitters Treatment2.932.37
Cohort 2 Standers and Walkers - Treatment5.526.56

Max CMAP Amplitude Median

The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmV (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment1.911.44
Cohort 1b Sitters Treatment2.21.8
Cohort 2 Standers and Walkers - Treatment5.35.85

Max CMAP Area (Mean)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Mean)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment5.465.28
Cohort 1b Sitters Treatment5.455.26
Cohort 2 Standers and Walkers - Treatment14.8516.26

Max CMAP Area (Median)

The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)

,,
InterventionmVms (Median)
Baseline6 months
Cohort 1a Sitters Placebo Then Treatment3.63.74
Cohort 1b Sitters Treatment4.63.4
Cohort 2 Standers and Walkers - Treatment13.6516.85

Modified Hammersmith Change From Baseline to 6 Months

Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months

,
InterventionScore (Mean)
Baseline visit (0 weeks)6 Month visit (V2)Change from Baseline
Cohort 1a Sitters Placebo Then Treatment20.020.60.6
Cohort 1b Sitters Treatment16.616.80.2

Modified Hammersmith Extend Baseline

"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)

InterventionScore (Mean)
Modified Hammersmith Extend at S1 (-4 weeks)Modified Hammersmith Extend at S2 (0 weeks)
Cohort 2 Experimental47.048.3

Reviews

13 reviews available for carnitine and Fatigue

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Carnitine derivatives beyond fatigue: an update.
    Current opinion in gastroenterology, 2023, 03-01, Volume: 39, Issue:2

    Topics: Carnitine; Fatigue; Fatty Acids; Humans; Oxidation-Reduction

2023
Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis.
    Nutrients, 2017, Nov-07, Volume: 9, Issue:11

    Topics: Carnitine; Dietary Supplements; Fatigue; Humans; Neoplasms

2017
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2015, May-30, Issue:5

    Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea

2015
Advances in pharmacologic strategies for cancer cachexia.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Amino Acids; Body Weight; Cachexia; Carnitine; Clinical Trials as Topic; Cytokines; Dietary Suppleme

2015
Ergogenic dietary aids for the elderly.
    Nutrition (Burbank, Los Angeles County, Calif.), 2012, Volume: 28, Issue:3

    Topics: Aged; Caffeine; Carnitine; Creatine; Diet; Drug Combinations; Elder Nutritional Physiological Phenom

2012
Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:4

    Topics: Anemia; Carnitine; Fatigue; Homeostasis; Humans; Hypotension; Kidney; Kidney Failure, Chronic; Renal

2003
Monograph. L-carnitine.
    Alternative medicine review : a journal of clinical therapeutic, 2005, Volume: 10, Issue:1

    Topics: Cardiovascular Diseases; Carnitine; Contraindications; Drug Interactions; Fatigue; Humans

2005
Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.
    Blood purification, 2006, Volume: 24, Issue:1

    Topics: Anemia; Carnitine; Drug Resistance; Erythropoietin; Fatigue; Hypotension; Randomized Controlled Tria

2006
A critical review of complementary therapies for cancer-related fatigue.
    Integrative cancer therapies, 2007, Volume: 6, Issue:1

    Topics: Acupuncture Therapy; Adenosine Triphosphate; Carnitine; Complementary Therapies; Energy Metabolism;

2007
Cancer-related fatigue. Clinical Practice Guidelines in Oncology.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:10

    Topics: Algorithms; Carnitine; Comorbidity; Counseling; Dietary Supplements; Disease Management; Fatigue; Hu

2007
[Fibromyalgia syndrome].
    Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:2

    Topics: Biomarkers; Carnitine; Diagnosis, Differential; Fatigue; Fatigue Syndrome, Chronic; Fibromyalgia; Hu

1999
[Relation of some nutritional supplements and physical performance].
    Archivos latinoamericanos de nutricion, 2000, Volume: 50, Issue:4

    Topics: Amino Acids, Branched-Chain; Carnitine; Chromium; Creatinine; Dietary Supplements; Exercise; Fatigue

2000

Trials

20 trials available for carnitine and Fatigue

ArticleYear
L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Nutrients, 2021, Sep-28, Volume: 13, Issue:10

    Topics: Adult; Age Factors; Biomarkers; Body Composition; Carnitine; Dietary Supplements; Exercise; Fatigue;

2021
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
    PloS one, 2020, Volume: 15, Issue:3

    Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cardiomyopathies; Carnitine; Dietary Supplements

2020
L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.
    American journal of medical genetics. Part A, 2021, Volume: 185, Issue:10

    Topics: Cardiomyopathies; Carnitine; Child; Dietary Supplements; Fatigue; Female; Humans; Hyperammonemia; Ma

2021
Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Carnitine; Dietary Supplements; Fatigue; Female;

2019
Effects of l-carnitine administration on health-related quality of life during cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.
    Auris, nasus, larynx, 2019, Volume: 46, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Chemoradiotherapy; Cisplatin; Fatigue; Fe

2019
Determining and surveying the role of carnitine and folic acid to decrease fatigue in β-thalassemia minor subjects.
    Pediatric hematology and oncology, 2013, Volume: 30, Issue:8

    Topics: Adolescent; beta-Thalassemia; Carnitine; Child; Child, Preschool; Dietary Supplements; Fatigue; Fema

2013
L-carnitine ameliorated fasting-induced fatigue, hunger, and metabolic abnormalities in patients with metabolic syndrome: a randomized controlled study.
    Nutrition journal, 2014, Nov-26, Volume: 13

    Topics: Administration, Intravenous; Adult; Alanine Transaminase; Blood Glucose; Blood Pressure; Body Mass I

2014
Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:2

    Topics: Adult; Aged; Breast Neoplasms; Carnitine; Fatigue; Female; Humans; Middle Aged; Quality of Life; Ubi

2016
L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment: a randomized, double-blind, placebo-controlled trial.
    Endocrine journal, 2016, Oct-29, Volume: 63, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Carnitine; Dietary Supplements; Double-Blind Method; Fatigue; Female

2016
Effects of L-carnitine on oxidative stress responses in patients with renal disease.
    Medicine and science in sports and exercise, 2010, Volume: 42, Issue:10

    Topics: Antioxidants; Carnitine; Catalase; Dietary Supplements; Exercise; Fatigue; Glutathione; Glutathione

2010
L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-01, Volume: 30, Issue:31

    Topics: Carnitine; Complementary Therapies; Dietary Supplements; Double-Blind Method; Fatigue; Female; Human

2012
L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
    Neuropsychobiology, 2003, Volume: 47, Issue:2

    Topics: Adult; Carnitine; Case-Control Studies; Chronic Disease; Drug Interactions; Fatigue; Female; Hepatit

2003
Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging.
    Urology, 2004, Volume: 63, Issue:4

    Topics: Aged; Aging; Carnitine; Climacteric; Depression; Drug Therapy, Combination; Erectile Dysfunction; Fa

2004
Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study.
    Journal of pain and symptom management, 2006, Volume: 32, Issue:6

    Topics: Administration, Oral; Carnitine; Dietary Supplements; Dose-Response Relationship, Drug; Drug Adminis

2006
L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2007, Volume: 39, Issue:10

    Topics: Administration, Oral; Adult; Biomarkers; Biopsy; Carnitine; Celiac Disease; Chromatography, High Pre

2007
L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial.
    The American journal of clinical nutrition, 2007, Volume: 86, Issue:6

    Topics: Adipose Tissue; Aged, 80 and over; Aging; Blood Pressure; Carnitine; Cholesterol; Cognition; Creatin

2007
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.
    Nutrition (Burbank, Los Angeles County, Calif.), 2008, Volume: 24, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antioxidants;

2008
Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Carbon Dioxide; Carnitine; Double-Blind Method; Exercise Test; Exercise Tolerance; Fati

2001
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam

2002

Other Studies

25 other studies available for carnitine and Fatigue

ArticleYear
The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy.
    Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:22

    Topics: Aged; Carnitine; Fatigue; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male

2021
Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
    Chemotherapy, 2022, Volume: 67, Issue:2

    Topics: Cardiomyopathies; Carnitine; Fatigue; Female; Humans; Hyperammonemia; Leukemia, Myelogenous, Chronic

2022
[Effectiveness of L-Carnitine in the Treatment of Fatigue Associated with Chemotherapy in Patients with Gastric Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:3

    Topics: Antineoplastic Agents; Carnitine; Fatigue; Humans; Stomach Neoplasms

2020
Non-targeted metabolomics analyses by mass spectrometry to explore metabolic stress after six training weeks in high level swimmers.
    Journal of sports sciences, 2021, Volume: 39, Issue:9

    Topics: Adolescent; Athletes; Butyric Acid; Carnitine; Cresols; Cross-Over Studies; Fatigue; Female; Glycoge

2021
Changes in carnitine levels through induction chemotherapy in head and neck cancer patients as a potential cause of therapy-related malaise.
    BMC cancer, 2021, Jun-28, Volume: 21, Issue:1

    Topics: Adult; Aged; Carnitine; Cisplatin; Fatigue; Head and Neck Neoplasms; Humans; Induction Chemotherapy;

2021
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015, Volume: 19, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela

2015
[Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carnitine; Fatigue; Female; Humans; Male; Mid

2014
Surprising results of a supportive integrated therapy in myelofibrosis.
    Nutrition (Burbank, Los Angeles County, Calif.), 2015, Volume: 31, Issue:1

    Topics: Anemia; C-Reactive Protein; Cachexia; Carnitine; Celecoxib; Curcumin; Erythropoietin; Fatigue; Ferri

2015
Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
    Journal of neuroimmunology, 2015, Jun-15, Volume: 283

    Topics: Adult; Aged; Carnitine; Chronic Disease; Comorbidity; Depression; Fatigue; Female; Gait Disorders, N

2015
A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2016, Volume: 32, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Chromatography, Liquid; Cross-Sectional Studies

2016
L-carnitine supplementation for the management of fatigue in patients with hypothyroidism on levothyroxine treatment [Letter to the Editor].
    Endocrine journal, 2016, 10-29, Volume: 63, Issue:10

    Topics: Carnitine; Dietary Supplements; Fatigue; Humans; Hypothyroidism; Thyroxine

2016
Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy.
    Oncology research and treatment, 2017, Volume: 40, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; beta 2-Microglobulin; Carnitine; Cisplatin; Fatigue; Female; Hum

2017
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

2009
Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Body Composition; Carnitine; Case-Control Studies; Electric Impedanc

2011
Fatigue and serum carnitine levels in chronic liver disease.
    Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:11

    Topics: Carnitine; Chronic Disease; Fatigue; Humans; Liver Diseases; Severity of Illness Index

2011
[Effects of fatigue and restraint stress on the expression of carnitine palmitoyltransferase-I and 5-hydroxytryptamine receptors in aorta of rats].
    Zhonghua yi xue za zhi, 2011, Apr-05, Volume: 91, Issue:13

    Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Endothelial Cells; Endothelin-1; Fatigue; Male

2011
L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis.
    Annals of the New York Academy of Sciences, 2004, Volume: 1033

    Topics: Carnitine; Depression; Dietary Supplements; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; R

2004
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.
    Nutrition (Burbank, Los Angeles County, Calif.), 2006, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carnitine; Cytokines; Dietary Supplements; Fatigue; Female; Glut

2006
Understanding and treating cancer-related fatigue.
    The journal of supportive oncology, 2006, Volume: 4, Issue:2

    Topics: Carnitine; Confounding Factors, Epidemiologic; Cytokines; Fatigue; Humans; Neoplasms; Vitamin B Comp

2006
Riboflavin-responsive complex I deficiency.
    Biochimica et biophysica acta, 1995, May-24, Volume: 1271, Issue:1

    Topics: Adolescent; Adult; Biopsy; Carnitine; Child; Consanguinity; Electron Transport Complex IV; Fatigue;

1995
L-carnitine combined with minimal electrical stimulation promotes type transformation of canine latissimus dorsi.
    Journal of applied physiology (Bethesda, Md. : 1985), 1994, Volume: 76, Issue:4

    Topics: Animals; Body Composition; Carnitine; Dogs; Electric Stimulation; Electrodes, Implanted; Electron Tr

1994
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Carnitine deficiency during valproic acid treatment.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 1995, Volume: 65, Issue:3

    Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Fatigue; Female; Humans; Infant; Ma

1995
Serum carnitine and disabling fatigue in multiple sclerosis.
    Psychiatry and clinical neurosciences, 1996, Volume: 50, Issue:6

    Topics: Adult; Carnitine; Fatigue; Fatigue Syndrome, Chronic; Female; Humans; Male; Mitochondria, Muscle; Mu

1996
Noninvasive evaluation of adult onset myopathy from carnitine palmitoyl transferase II deficiency using proton magnetic resonance spectroscopy.
    The Journal of rheumatology, 1999, Volume: 26, Issue:8

    Topics: Adult; Age of Onset; Biomarkers; Carnitine; Carnitine O-Palmitoyltransferase; Fatigue; Female; Human

1999
Normal carnitine levels in patients with chronic fatigue syndrome.
    The Netherlands journal of medicine, 2000, Volume: 57, Issue:1

    Topics: Adult; Carnitine; Case-Control Studies; Fatigue; Fatigue Syndrome, Chronic; Female; Humans; Middle A

2000